HIV-1 Infections Clinical Trial
Official title:
Pharmacokinetics of Pediatric Aluvia® (Lopinavir /Ritonavir 100/25 mg) and Generic Lopinavir/Ritonavir Tablet Formulation (200/50 mg) in Clinically and Virologically Stable HIV-1 Infected Thai Adults
The purpose of this study is to study the pharmacokinetics profiles of generic lopinavir/ritonavir and Pediatric Aluvia® at reduced dose by assessing safety, tolerability and efficacy.
This is a prospective, 2 arms, randomized intensive PK study with cross over design. This design will provide us optimal information to answer our research question. First and most important, we can assess the PK when lopinavir/r is used in a dose reduced form. By randomizing the patients to either Abbott's pediatric Aluvia dose reduction or India generic LPV/r dose reduction will allow us to assess the differences in AE severity and frequency. Using the standard abbott product as a control our study will provide important information about the bioavailability of the generic product. Although it's not an original BE design we must be able to make preliminary comparisons. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01013415 -
CD4-ZETA Gene Modified T Cells With and Without Exogenous Interleukin-2 (IL-2) In HIV Patients
|
Phase 1 | |
| Active, not recruiting |
NCT02923713 -
TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV
|
Phase 2 | |
| Completed |
NCT01151319 -
Safety and Immunogenicity Study of Three Candidate HIV-1 Vaccines, Administered in Combination to Healthy HIV-1 Uninfected Adults
|
Phase 1 | |
| Completed |
NCT01138605 -
TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV
|
Phase 2 | |
| Completed |
NCT01078233 -
Observational Data Analysis in EuroSIDA (MK-0518-058)
|
||
| Recruiting |
NCT02593409 -
HIV PrEP Priming of Immune Effectors
|
Phase 4 | |
| Completed |
NCT00557245 -
Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples
|
Phase 3 | |
| Withdrawn |
NCT00984152 -
Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women
|
Phase 3 | |
| Completed |
NCT00799058 -
A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States
|
Phase 1/Phase 2 | |
| Completed |
NCT01281813 -
TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV
|
Phase 3 | |
| Completed |
NCT01078246 -
Post-Licensure Safety Study of ISENTRESS™ (Raltegravir) in a United States Managed Care Network (MK-0518-268)
|
||
| Active, not recruiting |
NCT03027297 -
TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV
|
Phase 3 | |
| Completed |
NCT01139905 -
Lopinavir/Ritonavir (LPV/r) Tablet in HIV Infected Children
|
Phase 2 | |
| Completed |
NCT01033760 -
Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)
|
Phase 3 | |
| Completed |
NCT00830804 -
Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults
|
Phase 2 | |
| Completed |
NCT01074931 -
Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China
|
N/A |